September 23rd 2020
Christopher Pleyer, MD, discusses the phase 2 trial examining fludarabine plus ibrutinib in CLL and SLL, the next steps for the research, and where future efforts should be focused.
September 22nd 2020
Erlene Seymour, MD, discusses the kinase selectivity of BTK inhibitors in chronic lymphocytic leukemia.
September 14th 2020
Jennifer Woyach, MD, discusses clinical trials examining novel triplet regimens in chronic lymphocytic leukemia.
Nilanjan Ghosh, MD, PhD, discusses approved BTK inhibitors in B-cell malignancies.
September 11th 2020
Jennifer Woyach, MD, discusses the safety profile of acalabrutinib compared with ibrutinib in chronic lymphocytic leukemia.
Acalabrutinib continued to show prolonged progression-free survival with a favorable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia, including those with high-risk features.
September 10th 2020
The European Commission has approved an expanded indication of ibrutinib for use in combination with rituximab in treatment-naïve adult patients with chronic lymphocytic leukemia.
Jennifer Woyach, MD, discusses the role of acalabrutinib in chronic lymphocytic leukemia.
Nilanjan Ghosh, MD, PhD, discusses remaining questions with BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Patients with chronic lymphocytic leukemia who are being treated with ofatumumab will soon have to get their therapy through an oncology patient access program, as Novartis will no longer be selling the drug commercially for this indication.
